Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

被引：0

作者：

Finn, Richard S.

Qin, Shukui

Ikeda, Masafumi

Galle, Peter R.

Ducreux, Michel

Kim, Tae-You

Kudo, Masatoshi

Lim, Ho Yeong

Breder, Valeriy Vladimirovich

Merle, Philippe

Kaseb, Ahmed Omar

Li, Daneng

Feng, Yin-Hsun

Verret, Wendy

Xu, Derek-Zhen

Hernandez, Sairy

Ding, Beiying

Zhu, Andrew X.

Cheng, Ann-Lii

机构：

[1] UCLA, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA

[2] Jinling Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Med Ctr, Mainz, Germany

[5] Gustave Roussy Canc Campus Grand Paris, Villejuif, France

[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea

[9] NN Blokhin Minist Hlth, Russian Oncol Res Ctr, Moscow, Russia

[10] Hosp La Croix Rousse, Lyon, France

[11] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA

[12] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

[13] Beckman Res Inst, Duarte, CA USA

[14] Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol, Tainan, Taiwan

[15] Genentech Inc, San Francisco, CA 94080 USA

[16] Roche Prod Dev, Shanghai, Peoples R China

[17] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[18] Natl Taiwan Univ Hosp, Taipei, Taiwan

[19] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4596

引用

页数：2

共 50 条

[21] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
Lu, Linbin
Zheng, Peichan
Pan, Yan
Huang, Shanshan
Shao, Erqian
Huang, Yan
Wang, Xuewen
Chen, Yayin
Cuo, Gongbao
Yang, Hongyi
Guo, Wangting
Shi, Yanhong
Wu, Zhixian
Chen, Xiong
BRITISH JOURNAL OF CANCER, 2023, 129 (04) : 620 - 625
[22] Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
Fulgenzi, Claudia A. M.
Murphy, Cian
D'Alessio, Antonio
Scheiner, Bernhard
Pinter, Matthias
Cortellini, Alessio
Pinato, David J. James
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 597 - 597
[23] Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Qin, Shukui
Ren, Zhenggang
Feng, Yin-Hsun
Yau, Thomas
Wang, Baocheng
Zhao, Haitao
Bai, Yuxian
Gu, Shanzhi
Li, Lindong
Hernandez, Sairy
Xu, Derek-Zhen
Mulla, Sohail
Wang, Yifan
Shao, Hui
Cheng, Ann Lii
LIVER CANCER, 2021, 10 (04) : 296 - 308
[24] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
Linbin Lu
Peichan Zheng
Yan Pan
Shanshan Huang
Erqian Shao
Yan Huang
Xuewen Wang
Yayin Chen
Gongbao Cuo
Hongyi Yang
Wangting Guo
Yanhong Shi
Zhixian Wu
Xiong Chen
British Journal of Cancer, 2023, 129 : 620 - 625
[25] IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.
Kudo, Masatoshi
Tsuchiya, Kaoru
Shao, Yu Yun
Finn, Richard S.
Galle, Peter R.
Ducreux, Michel
Cheng, Ann-Lii
Yamashita, Tatsuya
Koga, Hironori
Aoki, Kenichi
Yamada, Kyoko
Asakawa, Takashi
Nakagawa, Yuki
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 538 - 538
[26] Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma
Roy, Akash
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (06) : 1575 - 1576
[27] IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
Breder, Valeriy Vladimirovich
Vogel, Arndt
Merle, Philippe
Finn, Richard S.
Galle, Peter R.
Zhu, Andrew X.
Cheng, Ann-Lii
Feng, Yin-Hsun
Li, Daneng
Gaillard, Vincent E.
Li, Lindong
Nicholas, Alan
Lencioni, Riccardo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Cheng, Ann-Lii
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Lim, Ho Yeong
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Ma, Ning
Nicholas, Alan
Wang, Yifan
Li, Lindong
Zhu, Andrew X.
Finn, Richard S.
JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 862 - 873
[29] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
Salem, Riad
Galle, Peter
Finn, Richard
Ducreux, Michel
Singal, Amit
Nicholas, Alan
Hernandez, Sairy
Verret, Wendy
Merle, Philippe
Zhu, Andrew
JOURNAL OF HEPATOLOGY, 2021, 75 : S246 - S247
[30] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Kudo, Masatoshi
Finn, Richard S.
Cheng, Ann-Lii
Zhu, Andrew X.
Ducreux, Michel
Galle, Peter R.
Sakamoto, Naoya
Kato, Naoya
Nakano, Michitaka
Jia, Jing
Vogel, Arndt
LIVER CANCER, 2023, 12 (05) : 479 - 493

← 1 2 3 4 5 →